Venofer® Reimbursement Hotline: 1-800-282-7712
FOR NON-DIALYSIS FACILITIES AND PROVIDERS ONLY

American Regent, Inc. has created a toll-free hotline to help physicians and other providers understand payer’s coverage and reimbursement policies for Venofer® (iron sucrose injection, USP) and, when necessary, address reimbursement issues. Specifically, hotline Reimbursement Specialists assist with the following:

  • Insurance verifications. Help callers verify payer coverage and reimbursement policies for Venofer® for specific patients with patient consent. Reimbursement specialists will determine patients’ benefits level and discuss potential billing options.
  • Billing assistance. Assist callers with filing claims and understanding the reimbursement policies for Venofer®, including researching state-specific local codes.
  • Claims appeals. Support callers in appealing denied claims or inadequate reimbursement for Venofer®.
  • Patient assistance. Screen individuals with no health insurance who are ineligible for public assistance for enrollment in a free product replacement program.

Instructions on Using the Reimbursement Hotline

  • Hours of operation are Monday through Friday from 9:00 AM to 5:00 PM, Eastern time. Call toll-free 800-282-7712
  • A Reimbursement Specialist answers most calls. There may be times when you need to leave a message that includes your name, telephone number, and a brief summary of your question or request. Calls are returned on the same day, or within one business day whenever possible
  • During your call, you will be asked to provide the following information:
    - Name and telephone number(s) of the patient's primary and secondary third-party payer(s)
    - Patient's name, date of birth, policy holder's name, and policy number(s)
    - Your reimbursement questions

Patient information will be kept strictly confidential at all times

The Reimbursement Specialist will either provide you with the information you request or will contact the insurer for clarification. The Reimbursement Specialist will call you back with the information you requested.

There is no limit to the number of times you call or the number of cases you may discuss with the Reimbursement Specialist, and there is no charge for this service.

Every attempt is made to provide accurate, up-to-date information. The Venofer® Reimbursement Hotline cannot guarantee successful reimbursement.

For more details about coverage and reimbursement, call the Venofer® Reimbursement Hotline at 800-282-7712, Monday through Friday, 9:00 AM to 5:00 PM, Eastern time.

For Customer Service or Professional Services Departments, call 800-645-1706.



American Regent. Enriching the lives of anemia patients. ™

IMPORTANT SAFETY INFORMATION: Venofer® (iron sucrose injection, USP) is contraindicated in patients with evidence of iron overload, in patients with known hypersensitivity to VenoferŪ or any of its inactive components, and in patients with anemia not caused by iron deficiency. Serious hypersensitivity reactions have been reported in patients receiving VenoferŪ. In clinical studies, several patients experienced hypersensitivity reactions presenting with wheezing, dyspnea, hypotension, rashes, or pruritus. The post-marketing spontaneous reporting system includes reports of patients who experienced serious or life-threatening reactions (anaphylactic shock, loss of consciousness or collapse, bronchospasm with dyspnea, or convulsion) associated with VenoferŪ administration.

Hypotension has been reported frequently in non-dialysis dependent-CKD patients receiving IV iron. Hypotension following administration of VenoferŪ may be related to rate of administration and total dose delivered.

In a multi-dose efficacy study in non-dialysis dependent-CKD patients (N=91), the most frequent adverse events (≥5%) whether or not related to VenoferŪ administration, were taste disturbance (7.7%), peripheral edema (7.7%), diarrhea (5.5%), constipation (5.5%), nausea (5.5%), dizziness (5.5%), and hypertension (5.5%). In an additional study of VenoferŪ with varying erythropoietin doses in 96 treated NDD-CKD patients, adverse events, whether or not related to VenoferŪ reported by ≥5% of VenoferŪ exposed patients are as follows: diarrhea (16.5%), edema (16.5%), nausea (13.2%), vomiting (12.1%), arthralgia (7.7%), back pain (7.7%), headache (7.7%), hypertension (7.7%), taste disturbance (7.7%), dizziness (6.6%), extremity pain (5.5%), and injection site burning (5.5%).

In multi-dose efficacy studies in HDD-CKD patients (N=231), the most frequent adverse events (> 5%) whether or not related to VenoferŪ administration, were hypotension (39.4%), muscle cramps (29.4%), nausea (14.7%), headache (12.6%), graft complications (9.5%), vomiting (9.1%), dizziness (6.5%) hypertension (6.5%), chest pain (6.1%), and diarrhea (5.2%). In post-marketing safety studies in HDD-CKD patients (N=1051), the most frequent adverse events reported (>1%), whether or not related to VenoferŪ administration, were congestive heart failure, sepsis, and taste disturbance. In the study of PDD-CKD patients (N=75), the most frequent adverse events, whether or not related to VenoferŪ, reported by ≥5% of these patients were diarrhea (8.0%), peritoneal infection (8.0%) vomiting (8.0%), hypertension (8.0%), pharyngitis (6.7%), peripheral edema (5.3%), and nausea (5.3%).


Please see Full Prescribing Information.